|
Market Closed -
Sao Paulo
16:08:00 2026-10-28 EDT
|
5-day change | 1st Jan Change | ||
| 51.31 BRL | +5.25% |
|
+9.85% | +17.31% |
| 10-28 | US estrogen supply crunch widens as women seek alternatives to scarce patches | RE |
| 10-23 | CVS is trying out pharmacists in chronic health management | RE |
| Market Cap | 115B 618B 103B 95.43B 86.43B 161B 10,957B 163B 1,141B 454B 5,733B 432B 423B 18,202B | P/E 2026 * |
13.1x | P/E 2027 * | 12.4x |
|---|---|---|---|---|---|
| Enterprise Value | 167B 897B 150B 138B 125B 234B 15,899B 237B 1,656B 659B 8,319B 626B 613B 26,411B | EV / Sales 2026 * |
0.4x | EV / Sales 2027 * | 0.38x |
| Free-Float |
71.17% | Yield 2026 * |
2.96% | Yield 2027 * | 3.04% |
Last Transcript: CVS Health Corporation
| 1 day | +5.25% | ||
| 1 week | +9.85% | ||
| Current month | +15.04% | ||
| 1 month | +10.99% | ||
| 3 months | -7.08% | ||
| 6 months | +26.72% | ||
| Current year | +17.31% |
| 1 week | 46.7 |  | 51.7 |
| 1 month | 42.68 | | 51.7 |
| Current year | 36.78 | | 58.37 |
| 1 year | 36.78 | | 58.37 |
| 3 years | 26.82 | | 58.37 |
| 5 years | 26.82 | | 60.8 |
| 10 years | 20.23 | | 60.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
J. Joyner
CEO | Chief Executive Officer | 62 | 2024-10-16 |
Ali Keshavarz
PSD | President | - | - |
Brian Newman
DFI | Director of Finance/CFO | 57 | 2025-05-11 |
| Director | Title | Age | Since |
|---|---|---|---|
C. Brown
BRD | Director/Board Member | 74 | 2007-02-28 |
Anne Finucane
BRD | Director/Board Member | 73 | 2011-01-19 |
| Director/Board Member | 71 | 2015-03-04 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +5.25% | +9.85% | - | - | 115B | |
| -1.29% | -3.75% | +9.43% | +35.69% | 115B | |
| +2.95% | +0.83% | -0.69% | +105.61% | 100B | |
| +3.31% | +2.67% | +123.89% | +1,009.30% | 61.18B | |
| +1.53% | +1.62% | -6.81% | +89.51% | 29.09B | |
| +8.78% | +11.27% | +38.72% | +81.07% | 29.25B | |
| +1.26% | +2.80% | +37.77% | +92.37% | 27.02B | |
| +2.46% | -0.23% | +31.22% | +405.46% | 21.62B | |
| -0.72% | +5.53% | -18.98% | -7.55% | 20.81B | |
| +0.26% | -1.75% | -4.85% | +31.71% | 16.97B | |
| Average | +2.38% | +2.02% | +23.30% | +204.80% | 46.81B | |
| Weighted average by Cap. | +2.48% | +0.79% | +25.51% | +220.91% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 418B 2,246B 375B 347B 314B 587B 39,815B 594B 4,146B 1,651B 20,834B 1,569B 1,536B 66,141B | 430B 2,311B 386B 357B 323B 604B 40,959B 611B 4,265B 1,699B 21,433B 1,614B 1,580B 68,042B |
| Net income | 8.87B 47.69B 7.96B 7.36B 6.67B 12.46B 845B 12.61B 88.02B 35.06B 442B 33.3B 32.6B 1,404B | 9.32B 50.07B 8.36B 7.73B 7B 13.08B 888B 13.24B 92.42B 36.81B 464B 34.97B 34.23B 1,474B |
| Net Debt | 51.89B 279B 46.55B 43.04B 38.98B 72.83B 4,942B 73.71B 515B 205B 2,586B 195B 191B 8,210B | 48.85B 262B 43.82B 40.52B 36.7B 68.56B 4,652B 69.38B 484B 193B 2,434B 183B 179B 7,728B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-28 | R$51.31 | +5.25% | 232 |
| 26-10-27 | R$48.75 | -2.38% | 63 |
| 26-10-26 | R$49.94 | +4.04% | 375 |
| 26-10-23 | R$48.00 | +1.37% | 975 |
| 26-10-22 | R$47.35 | +1.37% | 640 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CVS Stock
- CVSH34 Stock
Select your edition
All financial news and data tailored to specific country editions
